Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural)  or those provided by our clients, compound management, hit identification and hit validation.  Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures. 

Keensight Capital to acquire a majority stake in Axxam, a leading European partner research organization in life sciences

Keensight Capital has reached an agreement to invest alongside management in Axxam.

Axxam has obtained a license from iPS Academia Japan to use iPS cells and iPS-derived cells for drug discovery services

With the aim to offer drug discovery services using human induced pluripotent stem cells (iPS cells) and iPS-derived cells, Axxam has entered into a license agreement with iPS Academia Japan.

Subscribe to Our Newsletter

Follow us on